GENESIS Pharma is a biopharmaceutical company specializing in the commercialization of innovative pharmaceutical products for serious and rare diseases in Central and Eastern Europe.
Established in 1997, by a group of people who recognized early on the power and potential of pharmaceutical biotechnology, GENESIS Pharma was the first pharmaceutical company in Greece and one of the first in Europe to focus on the commercialization of new and innovative biopharmaceutical products. Shortly after its founding, the company began to steadily expand at a regional level, today covering most countries in the CEE region.The robust network of its strategic partnerships comprises leading international pharmaceutical companies dedicated to cutting-edge R&D, alongside fast-growing biopharmaceutical companies with pioneering research and disruptive innovations in the development of targeted, specialized treatments for orphan diseases.
In total, GENESIS Pharma holds a product portfolio covering over 30 serious and rare diseases, predominantly within the therapeutic areas of neurology, genetic diseases, oncology, hematology, rheumatology, dermatology, nephrology, gastroenterology, and cardiology.
Our story
-
1997
- Founding of GENESIS Pharma S.A.
- Initiation of partnership with Biogen & Vifor Pharma (now CSL Vifor)
-
1999
- Founding of GENESIS Pharma Cyprus Ltd
-
2001
- Initiation of business activity in other European markets
-
2003
- First distinction in Best Workplaces Hellas (13 years of distinctions in the Index in total)
-
2005
- Creation of Logistics Center in Athens
- Among the 100 best employers in Best Workplaces Europe (2005-2008)
-
2006
- First ISO 9001 quality management certification
- EUROPE'S 500 among the fastest growing companies in Europe
-
2007
- Initiation of partnership with PharmaMar
-
2009
- European distinction EFQM Committed to Excellence
- The first pharmaceutical company in Greece to be distinguished for CSR (CRI Index), with continuous distinctions to date in sustainable development by various organizations
-
2013
- European distinction EFQM Recognized for Excellence 4 star
- Costas Evripides (CEO) is named European Quality Leader (EOQ)
-
2015
- European Business Awards Ruban d’ Honneur among the top 110 companies in Europe
-
2016
- Initiation of partnership with Incyte & Vifor Fresenius Medical Care Renal Pharma
- First T certification
-
2018
- Initiation of partnership with Amicus Therapeutics
-
2019
- Initiation of partnership with Alnylam Pharmaceuticals
-
2021
- Initiation of partnership with Jazz Pharmaceuticals
- First ISO 27001 information security management certification
-
2022
- Initiation of partnership with Kyowa Kirin
-
2023
- Initiation of partnership with Deciphera Pharmaceuticals & Regeneron Pharmaceuticals
-
2024
- Initiation of partnership with Santhera Pharmaceuticals
- ISO 37001 anti-bribery management certification